Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the accuracy of [18F]-choline (FCH) positron emission tomography/computed tomography (PET/CT) for staging and restaging of prostate cancer.

Methods

FCH PET/CT was performed in 111 patients with prostate cancer using 200 MBq FCH: 43 patients [mean age 63 years; mean prostrate specific antigen (PSA) 11.58 μg/l] were examined for initial staging, and 68 patients (mean age 66.4 years) were examined for restaging (mean PSA 10.81 μg/l). FCH PET/CT results were correlated to histopathology, bone scan, morphology as revealed by magnetic resonance imaging (MRI) and CT, PET/CT follow-up and PSA follow-up after therapy.

Results

FCH PET/CT scans at initial staging correctly showed no metastases in 36/38 patients undergoing radical surgery, as confirmed by PSA levels <0.1 μg/l 6 months postoperatively. Lymphadenectomy was performed in 24 of these patients, revealing four false FCH-negative lymph nodes (LN). In one patient, only lymphadenectomy was performed since a FCH-positive LN was confirmed by histology. Four patients showed FCH-positive bone metastases, as proven by bone scan. FCH PET/CT scans at restaging correctly revealed local recurrence in 36 patients. No pathological FCH uptake was observed in 11 patients with biochemical recurrence. Twenty-three patients showed FCH-positive LN. Twenty LN were surgically removed in seven patients. Histopathology verified metastases in all LN, but revealed two additional metastastic, FCH-negative LN. Seventeen patients showed FCH-positive bone metastases, as proven by bone scan or MRI. Sensitivity to detect recurrent disease was 86%.

Conclusion

The results obtained using FCH PET/CT scans for initial N-staging were discouraging, especially in terms of its inability to detect small metastases. Recurrent disease can be localized reliably in patients with PSA levels of >2 μg/l.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 2005; 55:10–30.

  2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H. EAU guidelines on prostate cancer. Eur Urol 2005; 48:546–51.

  3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S–93S.

    PubMed  CAS  Google Scholar 

  4. Hautzel H, Muller-Mattheis V, Herzog H, Roden W, Coenen HH,. Ackermann R, et al. The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging. Urologe A 2002; 41:569–76.

  5. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 2002; 29:1283–8.

    Article  PubMed  Google Scholar 

  6. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43:187–99.

    PubMed  CAS  Google Scholar 

  7. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61:110–7.

  8. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415–9.

  9. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990–5.

    PubMed  CAS  Google Scholar 

  10. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovo MG. [18]F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387–1398.

  11. Schmid DT, John H, Zweifel R, Cservenyak T, Wetsera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235:623–8.

  12. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. [11]C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176:954–60.

  13. Reske SN, Blumstein NM, Neumaier B, Gottfried HW. et al. Imaging prostate cancer with 11C-Choline PET/CT. J Nucl Med 2006; 47:1249–54.

  14. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein P, Lieskovsky G, Skinner DG, Coteet RJ. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24:2735–42.

  15. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68:121–5.

    Article  PubMed  Google Scholar 

  16. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA<10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50:272–9.

    Article  PubMed  Google Scholar 

  17. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤10 ng/mL and biopsy Gleason score of ≤6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006; 97:1173–8.

    Article  PubMed  Google Scholar 

  18. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36:73–92.

    Article  PubMed  Google Scholar 

  19. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61:365–9.

    Article  PubMed  Google Scholar 

  20. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491–9.

  21. Cornud F, Bellin MF, Portalez D. MRI and staging evaluation of prostate cancer. J Radiol 2006; 87:228–43.

    PubMed  CAS  Google Scholar 

  22. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004; 231:379–85.

  23. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006; 8:43–8.

  24. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273–80.

    Article  PubMed  Google Scholar 

  25. Poissonnier L, Chapelon JY, Rouviere O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2006; 51:381–387.

  26. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176:2014–18; discussion 2018–19.

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital of Zurich, C NUK 8a, Raemistrasse 100, 8091, Zürich, Switzerland

    Daniela B. Husarik, Tibor Cservenyàk & Thomas F. Hany

  2. Department of Radiation Oncology, University Hospital Geneva, Geneva, Switzerland

    Raymond Miralbell

  3. Department of Urology, Hospital of Uster, Uster, Switzerland

    Markus Dubs

  4. Department of Urology, Klinik Hirslanden, Zurich, Switzerland

    Hubert John

  5. Department of Pathology, University Hospital Zurich, Zurich, Switzerland

    Olivier T. Giger

  6. Department of Urology and Transplantation, Edouard Herriot Hospital, Lyon, France

    Albert Gelet

Authors
  1. Daniela B. Husarik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond Miralbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus Dubs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hubert John
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier T. Giger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Albert Gelet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tibor Cservenyàk
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas F. Hany
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela B. Husarik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Husarik, D.B., Miralbell, R., Dubs, M. et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35, 253–263 (2008). https://doi.org/10.1007/s00259-007-0552-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0552-9

Keywords

Search

Navigation